Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.24.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Grant revenue $ 7,466 $ 37,653
Operating expenses:        
Research and development 879,041 769,350 2,449,234 4,448,623
General and administrative 1,558,239 1,332,562 4,754,149 3,697,609
Total operating expenses 2,437,280 2,101,912 7,203,383 8,146,232
Loss from operations (2,437,280) (2,094,446) (7,203,383) (8,108,579)
Other income (expense):        
Interest income 9,466 50,613 35,106 171,768
Interest expense (9,971) (14,170) (18,859) (18,360)
Other income 45,118 46,863
Foreign currency exchange net (25,085) (31,659)
Total other income (expense), net (25,590) 81,561 (15,412) 200,271
Loss before income taxes (2,462,870) (2,012,885) (7,218,795) (7,908,308)
Income tax benefit
Net loss $ (2,462,870) $ (2,012,885) $ (7,218,795) $ (7,908,308)
Basic net loss per share $ (0.38) $ (0.85) $ (1.49) $ (3.70)
Diluted net loss per share $ (0.38) $ (0.85) $ (1.49) $ (3.70)
Shares used to compute basic net loss per share 6,528,064 2,356,065 4,857,182 2,136,340
Shares used to compute diluted net loss per share 6,528,064 2,356,065 4,857,182 2,136,340